ALKS
Alkermes plc · Healthcare
Insiders sold $10.0M of Alkermes plc in the last 12 months and bought none
ALKS over the last year
ALKS after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
213 insider filings since 2016, newest first
Paul J Mitchell · Director
Paul J Mitchell · Director
David W Anstice · Director
Paul J Mitchell · Director
Paul J Mitchell · Director
Paul J Mitchell · Director
Paul J Mitchell · Director
Paul J Mitchell · Director
Floyd E Bloom · Director
Paul J Mitchell · Director
James M Frates · SVP, Alks Inc; CFO ALKS
Paul J Mitchell · Director
Michael J Landine · SVP, Corp Dev., Alkermes, Inc.
Richard F Pops · Dir, CEO, Alkermes plc
Michael J Landine · SVP, Corp Dev., Alkermes, Inc.
Richard F Pops · Dir, CEO, Alkermes plc
Richard F Pops · Dir, CEO, Alkermes plc
Paul J Mitchell · Director
Richard F Pops · Dir, CEO, Alkermes plc
Paul J Mitchell · Director
Paul J Mitchell · Director
Mark Stejbach · SVP, Chief Comm Off, Alks Inc
Shane Cooke · Pres, Alkermes plc
Paul J Mitchell · Director
Shane Cooke · Pres, Alkermes plc
Shane Cooke · Pres, Alkermes plc
Paul J Mitchell · Director
Iain Michael Brown · SVP Finance, CAO, Alks Inc.
Laurie Keating · SVP, General Counsel and Secretary
Paul J Mitchell · Director
James M Frates · SVP, Alks Inc; CFO ALKS
James M Frates · SVP, Alks Inc; CFO ALKS
Richard F Pops · Dir, CEO, Alkermes plc
Paul J Mitchell · Director
Michael J Landine · SVP, Corp Dev., Alkermes, Inc.
Paul J Mitchell · Director
Kathryn L Biberstein · EVP, CAO, CCO Alks Inc; Sec AL
Paul J Mitchell · Director
Paul J Mitchell · Director
Paul J Mitchell · Director
Mark Stejbach · SVP, Chief Comm Off, Alks Inc
Shane Cooke · Pres, Alkermes plc
Paul J Mitchell · Director
Richard F Pops · Dir, CEO, Alkermes plc
Michael J Landine · SVP, Corp Dev., Alkermes, Inc.
Richard F Pops · Dir, CEO, Alkermes plc
Michael J Landine · SVP, Corp Dev., Alkermes, Inc.
Richard F Pops · Dir, CEO, Alkermes plc
Shane Cooke · Pres, Alkermes plc
Shane Cooke · Pres, Alkermes plc
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.